TLPPF (Telix Pharmaceuticals) Other Current Receivables : $-0.1 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Other Current Receivables?

Telix Pharmaceuticals's Other Current Receivables for the quarter that ended in Jun. 2024 was $-0.1 Mil.

Telix Pharmaceuticals's quarterly Other Current Receivables stayed the same from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) and stayed the same from Dec. 2023 ($0.00 Mil) to Jun. 2024 ($-0.08 Mil).

Telix Pharmaceuticals's annual Other Current Receivables declined from Dec. 2021 ($13.37 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Telix Pharmaceuticals Other Current Receivables Historical Data

The historical data trend for Telix Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Other Current Receivables Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Receivables

Get a 7-Day Free Trial

7.80

9.22

13.37

Telix Pharmaceuticals Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Current Receivables	Get a 7-Day Free Trial									-	-	-	-	-0.08

Telix Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

Telix Pharmaceuticals Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Other Current Receivables

Comparable Companies

Traded in Other Exchanges

TLX:USA T3X:Germany TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.